Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
December 10, 2018 16:49 ET
|
Constellation Pharmaceuticals , Inc.
Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPCSingle-arm CPI-1205 / abiraterone / prednisone combination added to...
Constellation Pharmaceuticals to Present at BMO Healthcare Conference
November 29, 2018 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer
November 29, 2018 09:22 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics...
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
November 15, 2018 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
November 08, 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
Company Executing on Lead Programs CPI-1205 and CPI-0610Expects to Evaluate Proof of Concept for Both Programs in Mid-2019 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Constellation...
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
November 02, 2018 13:08 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
November 01, 2018 07:00 ET
|
Constellation Pharmaceuticals , Inc.
- Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...
Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker Award
September 12, 2018 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today congratulated Dr. C. David Allis and Dr. Michael Grunstein, the co-recipients of the...
Constellation Pharmaceuticals Announces Appointments to Board of Directors
September 04, 2018 06:30 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...